The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
# Background There are sparse data addressing whether standard risk factors for febrile neutropenia (FN) are relevant in patients receiving myelosuppressive chemotherapy and primary prophylaxis for FN, which would have implications for variables to consider during real-world comparative analyses of...
Saved in:
| Main Authors: | Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2021-06-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.24564 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim
by: Tomonori Makiguchi, et al.
Published: (2025-06-01) -
CHEMOTHERAPY-INDUCED NEUTROPENIA IN HIV POSITIVE PATIENTS WITH LYMPHOMA: COMPARISON OF PEGFILGRASTIM WITH DAILY FILGRASTIM ADMINISTRATION.
by: Luciana Teofili, et al.
Published: (2012-01-01) -
Assessment of chemotherapy-induced febrile neutropenia in cancer patients
by: Malona Lilly Philip, et al.
Published: (2019-01-01) -
Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
by: Paola Villafuerte-Gutierrez, et al.
Published: (2014-01-01) -
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
by: Advani S, et al.
Published: (2010-01-01)